CRC organoid has been established as a biobank to explore the efficacy of single and combined use of different inhibitors in RAS/RNF43-mutant CRC [254–256], the repurposing drugs [257], and identify the biomarkers predicting sensitivity to EGFR inhibitors [258]. The gene discussed is RNF43; the disease is colorectal carcinoma.